AbCellera Biologics Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
ABCL$12.46-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Loss and Comprehensive Loss
(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)
| Three months ended March 31, | ||
|---|---|---|
| 2025 | 2026 | |
| Revenue: | ||
| Research fees | $4,068 | $8,124 |
| Licensing and royalty revenue | 167 | 191 |
| Total revenue | 4,235 | 8,315 |
| Operating expenses: | ||
| Research and development(1) | 42,496 | 46,662 |
| Sales, general, and administrative(1) | 19,068 | 12,334 |
| Depreciation and amortization | 5,331 | 6,838 |
| Total operating expenses | 66,895 | 65,834 |
| Loss from operations | (62,660) | (57,519) |
| Other income: | ||
| Interest and other | (5,523) | (3,643) |
| Grants and incentives | (4,153) | (4,339) |
| Total other income | (9,676) | (7,982) |
| Loss before income tax | (52,984) | (49,537) |
| Income tax recovery | (7,363) | (6,372) |
| Net loss | $(45,621) | $(43,165) |
| Foreign currency translation adjustment | (2,620) | 1,815 |
| Comprehensive loss | $(48,241) | $(41,350) |
| Net loss per share | ||
| Basic | $(0.15) | $(0.14) |
| Diluted | $(0.15) | $(0.14) |
| Weighted-average common shares outstanding | ||
| Basic | 297,692,663 | 303,074,605 |
| Diluted | 297,692,663 | 303,074,605 |
(1)Exclusive of depreciation and amortization
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.